Harlem, been waiting for the same thing...the crazy thing is they dont even indicate anything is in the pipeline. They spent a majority of the 4th Qtr call defending their JUUL investment decision. They also consider the vaping category part of 'smokeless tobacco'...I get it...it's vapor and not smoke...but let's face it, anything absorbed via the lungs should be in the 'smoking' category. I also understand that this is still early. I believe the R&D was a three year agreement? I guess Altria wants to be 100% sure...and have the research to back up the claims, before recognizing the technology (you know like the research they did before investing in JUUL). By the end the research should lay the groundwork for any other DehydraTECH pairing. But what really confused me was Altria just taking the JUUL investment decision straight on the chin...and not at least trying to give their shareholders some comfort in future product direction (not only because of JUUL, and the FDA concerns, but also because cigarette smoking has been in decline). I was on the presentation webcast. I wanted to ask a question, but you could only do so via phone conference, so I sent investor relations an email asking about the status of their Lexy investment/research. They replied promptly but directed me to contact Chris Bunka for the update. I dont understand the game of he said; she said...unless they are banking on it being the ace up their sleeve...and really dont want the rest of their competition in the industry to catch on. The 12M investment...as opposed to the billions spent on other things...could have been a low amount agreed to in an effort to not raise any eyebrows. I am sure Bunka would be okay with this provided the amount covers their research/operation needs AND is heavy on the royalty side (before eventual US Nicotine license buyout).
News 
Market Data 
Discover 
